Whittier Trust Co. Decreases Holdings in Johnson & Johnson $JNJ

Whittier Trust Co. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 190,268 shares of the company’s stock after selling 15,373 shares during the period. Whittier Trust Co.’s holdings in Johnson & Johnson were worth $29,063,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. GFG Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on JNJ shares. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. HSBC boosted their target price on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Bank of America boosted their target price on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. Finally, The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $200.06.

Johnson & Johnson Stock Down 0.9%

JNJ opened at $191.93 on Wednesday. The business has a 50 day moving average price of $181.27 and a two-hundred day moving average price of $165.37. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market cap of $462.23 billion, a PE ratio of 18.53, a P/E/G ratio of 2.28 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.